MedTrace Logo

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

NCT00610935 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2021-03-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and effectivess of a single intramuscular injection of peramivir for the treatment of subjects with acute, uncomplicated influenza.

Conditions

Interventions

DRUG

Peramivir

To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.

DRUG

Placebo

Single intramuscular injection

Sponsors & Collaborators

  • BioCryst Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00610935 on ClinicalTrials.gov